onc Videos

Videos

Videos

Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL

06/22/2023

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.

At the 2023 ASCO Annual Meeting...

06/22/2023

Oncology

Omid Hamid, MD, The Angeles Clinic & Research Institute

Videos

Fianlimab Plus Cemiplimab Induces High Clinical Activity Response for Patients With Advanced Melanoma

06/21/2023

At the 2023 ASCO Annual Meeting, Omid Hamid, MD, shares results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma.

At the 2023 ASCO Annual Meeting,...

06/21/2023

Oncology

Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain

Videos

Chemotherapy De-escalation for HER2-Positive Early Breast Cancer

06/21/2023

Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

Javier Cortes, MD, PhD,...

06/21/2023

Oncology

Videos

Brexucabtagene Autoleucel Treatment for Patients With R/R Mantle Cell Lymphoma: Real-World Outcomes

06/21/2023

Swetha Kambhampati , MD;

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Debra Richardson, MD, Stephenson Cancer Center

Videos

Real-World Effectiveness of PARP Inhibitor Maintenance Therapy for Patients With Advanced Ovarian Cancer

06/21/2023

Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.

Debra Richardson, MD, discusses...

06/21/2023

Oncology

Videos

Long-Term Outcomes of CAR T-Cell Therapy for Patients With Relapsed/Refractory CLL

06/21/2023

Emily C. Liang , MD;

At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Videos

MAJIC-PV Study Indicates Ruxolitinib Treatment Yields Superior Responses for Patients With Polycythemia Vera

06/21/2023

Claire Harrison , MD;

Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...

Claire Harrison, MD, presents...

06/21/2023

Oncology

Videos

Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC

06/19/2023

At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

06/19/2023

Oncology

Valerie Crolley, MBBS, MRCP, University College London

Videos

Potentially Targetable Mutations Among Patients With Intrahepatic Cholangiocarcinoma

06/19/2023

At the 2023 ASCO Annual Meeting, Valerie Crolley, MBBS, MRCP, discusses potentially targetable mutations among patients with intrahepatic cholangiocarcinoma from the BILCAP trial.

At the 2023 ASCO Annual Meeting,...

06/19/2023

Oncology

Videos

Frontline Treatment With Epcoritamab Plus R-CHOP for Patients With High-Risk DLBCL

06/19/2023

Lorenzo Falchi, MD presents updated EPCORE NHL-2 data on epcoritamab combined with R-CHOP for the treatment of patients with high-risk diffuse large B-cell lymphoma.

Lorenzo Falchi, MD presents...

06/19/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology